PDP Access Steering Committee

Contact Us


Positive phase 1 results for iOWH032

An important milestone reached in our diarrheal disease program with the completion of two phase 1 clinical studies for iOWH032—our investigational new drug to treat acute secretory diarrhea caused by diseases such as cholera. PATH’s drug development program announces positive phase 1 results for its anti-diarrheal medication Link to press release

RTS,S malaria candidate vaccine

RTS,S malaria candidate vaccine reduces malaria by approximately one-third in African infants – Results from ongoing Phase III clinical trial announced. Link to press release Link to article pdf